Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, United States.
Front Cell Infect Microbiol. 2020 Dec 4;10:607663. doi: 10.3389/fcimb.2020.607663. eCollection 2020.
The incidence of Kaposi's sarcoma-associated herpesvirus (KSHV)-associated Kaposi Sarcoma has declined precipitously in the present era of effective HIV treatment. However, KSHV-associated lymphoproliferative disorders although rare, have not seen a similar decline. Lymphoma is now a leading cause of death in people living with HIV (PLWH), indicating that the immune reconstitution provided by antiretroviral therapy is not sufficient to fully correct the lymphomagenic immune dysregulation perpetrated by HIV infection. As such, novel insights into the mechanisms of KSHV-mediated pathogenesis in the immune compartment are urgently needed in order to develop novel therapeutics aimed at prevention and treatment of KSHV-associated lymphoproliferations. In this review, we will discuss our current understanding of KSHV molecular virology in the lymphocyte compartment, concentrating on studies which explore mechanisms unique to infection in B lymphocytes.
在当前有效的 HIV 治疗时代,卡波西肉瘤相关疱疹病毒(KSHV)相关卡波西肉瘤的发病率急剧下降。然而,尽管 KSHV 相关淋巴增生性疾病很少见,但并没有出现类似的下降。淋巴瘤现在是 HIV 感染者(PLWH)死亡的主要原因,这表明抗逆转录病毒疗法提供的免疫重建不足以完全纠正 HIV 感染引起的淋巴瘤免疫失调。因此,迫切需要深入了解 KSHV 在免疫区室中的发病机制的机制,以便开发旨在预防和治疗 KSHV 相关淋巴增生的新疗法。在这篇综述中,我们将讨论我们目前对淋巴细胞区室中 KSHV 分子病毒学的理解,重点讨论探索 B 淋巴细胞感染特有机制的研究。